Tate & Lyle plc (LON:TATE – Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 428.27 and traded as high as GBX 560.50. Tate & Lyle shares last traded at GBX 559, with a volume of 800,884 shares.
Analyst Ratings Changes
A number of research analysts have recently commented on TATE shares. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a GBX 595 price objective on shares of Tate & Lyle in a report on Friday, June 26th. Berenberg Bank upped their target price on Tate & Lyle from GBX 464 to GBX 554 and gave the stock a “hold” rating in a research report on Wednesday, May 27th. Finally, UBS Group reaffirmed a “neutral” rating and set a GBX 375 target price on shares of Tate & Lyle in a research report on Monday, May 18th. One research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Tate & Lyle presently has a consensus rating of “Hold” and an average price target of GBX 516.
Get Our Latest Stock Report on Tate & Lyle
Tate & Lyle Stock Down 0.1%
Tate & Lyle (LON:TATE – Get Free Report) last released its earnings results on Thursday, May 21st. The company reported GBX 22 earnings per share for the quarter. Tate & Lyle had a net margin of 4.84% and a return on equity of 6.17%. The firm had revenue of GBX 200.60 billion during the quarter. As a group, equities research analysts forecast that Tate & Lyle plc will post 51.3392857 EPS for the current year.
Tate & Lyle Company Profile
Tate & Lyle PLC, together with its subsidiaries, provides ingredients and solutions to the food, beverage, and other industries in the United States, the United Kingdom, other European countries, and internationally. It operates through three segments: Food & Beverage Solutions, Sucralose, and Primary Products. The company offers dairy products, soups, sauces, and dressings; bakery products and snacks; texturants; nutritive sweeteners, such as high fructose corn syrup and dextrose; fibres; and stabilizers and functional systems.
Read More
- Five stocks we like better than Tate & Lyle
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Tate & Lyle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tate & Lyle and related companies with MarketBeat.com's FREE daily email newsletter.
